Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D4JU8H
|
|||
| Drug Name |
MK-2118
|
|||
| Drug Type |
Small molecular drug
|
|||
| Indication | Lymphoma [ICD-11: 2A80-2A86; ICD-9: 202.8, 208.9] | Phase 1 | [1] | |
| Solid tumour/cancer [ICD-11: 2A00-2F9Z; ICD-10: C00-D48; ICD-9: 140-199] | Phase 1 | [2] | ||
| Company |
Merck
|
|||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Stimulator of interferon genes protein (TMEM173) | Target Info | Agonist | [3] |
| KEGG Pathway | NOD-like receptor signaling pathway | |||
| RIG-I-like receptor signaling pathway | ||||
| Cytosolic DNA-sensing pathway | ||||
| Human cytomegalovirus infection | ||||
| Herpes simplex virus 1 infection | ||||
| Human immunodeficiency virus 1 infection | ||||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) | |||
| REF 2 | ClinicalTrials.gov (NCT03249792) Study of MK-2118 Administered as Intratumoral Injection as Monotherapy and in Combination With Pembrolizumab (MK-3475) or by Subcutaneous Injection in Combination With Pembrolizumab in the Treatment of Adults With Advanced/Metastatic Solid Tumors or Lymphomas (MK-2118-001). U.S. National Institutes of Health. | |||
| REF 3 | National Cancer Institute Drug Dictionary (drug name ML2118). | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.